$CLOV

Soares Karen sold $22K of CLOV

Soares Karen (Chief Legal Officer) sold 4,681 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.61 on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Soares Karen
Published Jun 16, 2026, 12:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 12:37 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CLOV
Neutral
high confidence
Mentioned
$CLOV
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The newest fact is the officer’s open-market sale amount, price, and post-transaction holdings, disclosed as part of a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor insider activity for sentiment, but this specific disclosure is unlikely to drive a major repricing without additional fundamental catalysts.

03

What to watch

The article provides only the sale details; it does not indicate whether there were concurrent buys, option exercises, or broader insider activity trends.

Relevance 2/10Novelty 6/10Timing: Filed 2026-06-16; transaction dated 2026-06-15

Background

The article is an SEC Form 4 insider transaction disclosure for Clover Health Investments, Corp./DE.

Company-level read

Ticker impact

$CLOVNeutralHigh confidence
Context

Clover Health’s Chief Legal Officer Karen Soares sold 4,681 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect should be small and short-lived unless paired with other news.

Evidence & confidence

The filing is a standard officer sale with a stated 10b5-1 plan, providing disclosure but no new operating/regulatory/financial information.

Market effects

Minimal; this is company-specific insider transaction disclosure, not a sector-wide signal.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as confidence erosion, especially if it clusters with other negative signals.

Key entities

  • Clover Health Investments, Corp./DE

    Subject of the Form 4 insider transaction disclosure.

  • Karen Soares

    Chief Legal Officer who sold shares under a pre-arranged 10b5-1 plan.

Related articles

$CLOVMedAI 8/10

Clover Health Investments Q2 Earnings Call Highlights

Clover Health Investments (CLOV) reported Q2 adjusted EBITDA of $41 million and GAAP net income of $28 million. For the first half of 2026, it posted $81 million adjusted EBITDA and $55 million GAAP net income, with $443 million cash and investments and no debt. The company raised 2026 guidance to $2.92B-$3.0B revenue and $70M-$85M adjusted EBITDA, and discussed cohort maturation and 4.5-star ratings for 2027.

$METMed

Financial results round-up: MetLife, Prudential, Corebridge, Palomar, Heritage, TWFG, Root and more

A financial results roundup covers multiple insurers and MGAs. MetLife reported Q2 net income of $705m and adjusted EPS $2.43. Prudential posted Q2 net income of $985m and record individual life sales. Corebridge reported a $16m net loss and merger approval. Palomar, Heritage, TWFG, Root, Trupanion and Clover Health also reported Q2 figures and guidance updates.

$CLOVHighAI 9/10

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV): Results of Operations and Financial Condition

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q26exx991xearningsrelease.htm EX-99.1 Document Exhibit 99.1 Clover Health Reports Second Quarter 2026 Results Business Highlights: • Delivered strong second quarter 2026 GAAP Net Income alongside continued market-leading Medicare Advantage membership growth • Improved

$CLOVMed

What's Fueling Clover Health's Recent Stock Surge

Clover Health (CLOV) shares rose about 7% to $2.39 after UnitedHealth Group (UNH) reported strong Q1 2026 results and raised its full-year adjusted net earnings outlook to over $18.25 per share, lifting sentiment for health insurers. Clover also cited 53% YoY Medicare Advantage membership growth and reiterated 2026 GAAP net income profitability guidance. Analysts maintain a Hold rating and a $2.90 average target.